Autolus to Present at J.P. Morgan Healthcare Conference

January 5th, 2017

London, 5th January 2017 – Autolus Limited, a private biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours, announced today that Dr Christian Itin, Chief Executive Officer, is presenting at the 35th Annual J.P. Morgan Healthcare Conference on Monday 9 January 2017 at 7:30 a.m. PST at the Westin St. Francis Hotel, San Francisco, California.

– Ends –

Further information:

JW Communications
Julia Wilson
+44 (0)7818 430877
juliawilsonuk@gmail.com

Notes for Editors:

About Autolus

Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products based on its proprietary T-cell programming technology. Autolus’ shareholders include Syncona LLP, UCL Business PLC, Woodford Investment Management LLP and Arix Bioscience plc. For further information please visit the Company’s website at: www.autolus.com